John Vane

Q: What Schools Are Affiliated With John Vane

John Vane is affiliated with the following schools: University of Oxford, Royal Postgraduate Medical School, University of Birmingham, Queen Mary University of London, University of West Bohemia

John Vane's AcademicInfluence.com Rankings

John Vane

Medical

#11

World Rank

#22

Historical Rank

Pharmacology

World Rank

Historical Rank

medical Degrees

Download Badge

Medical

Why Is John Vane Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir John Robert Vane was a British pharmacologist who was instrumental in the understanding of how aspirin produces pain-relief and anti-inflammatory effects and his work led to new treatments for heart and blood vessel disease and introduction of ACE inhibitors. He was awarded the Nobel Prize in Physiology or Medicine in 1982 along with Sune Bergström and Bengt Samuelsson for "their discoveries concerning prostaglandins and related biologically active substances".

(See a Problem?)

John Vane's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. (1971) (8384)
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation (1976) (3173)
Cyclooxygenases 1 and 2. (1998) (2804)
Regulatory functions of the vascular endothelium. (1990) (2025)
EICOSAPENTAENOIC ACID AND PREVENTION OF THROMBOSIS AND ATHEROSCLEROSIS? (1978) (1668)
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. (1978) (1656)
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. (1993) (1596)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. (1999) (1527)
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. (1988) (1438)
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. (1979) (1160)
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. (1994) (1060)
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. (1976) (997)
The mechanism of action of aspirin. (2003) (957)
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. (1976) (949)
Indomethacin and aspirin abolish prostaglandin release from the spleen. (1971) (900)
HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATION (1977) (892)
Prostaglandins: Their Disappearance from and Release into the Circulation (1967) (887)
Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs (1969) (850)
Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol) (1972) (743)
Towards a better aspirin (1994) (708)
The chemical structure of prostaglandin X (prostacyclin). (1976) (689)
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. (1977) (689)
THE RELEASE OF PROSTAGLANDINS FROM LUNG AND OTHER TISSUES (1971) (658)
Anti-inflammatory drugs and their mechanism of action (1998) (655)
The release and fate of vaso‐active hormones in the circulation (1969) (623)
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. (1977) (595)
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. (1976) (594)
Conversion of Angiotensin I to Angiotensin II (1967) (587)
Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. (1990) (548)
An Enzyme Isolated from Arteries Transforms Prostaglandin Endoperoxides to an Unstable Substance that Inhibits Platelet Aggregation. (1977) (548)
New insights into the mode of action of anti-inflammatory drugs (2005) (548)
A SENSITIVE METHOD FOR THE ASSAY OF 5‐HYDROXYTRYPTAMINE (1997) (530)
Prostaglandins released by the Spleen (1968) (524)
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides (1976) (517)
Inactivation of Prostaglandins by the Lungs (1970) (517)
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid (1991) (515)
Inflammation and the mechanism of action of anti‐inflammatory drugs (1987) (496)
A new approach to anti-inflammatory drugs. (1979) (464)
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. (1972) (459)
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. (1990) (457)
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. (1978) (448)
Mechanism of action of nonsteroidal anti-inflammatory drugs. (1998) (446)
New Aspects of the Mode of Action of Nonsteroid Anti-Inflammatory Drugs (1974) (445)
Nitric oxide‐mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock (1993) (415)
Optical Projection Tomography as a Tool for 3D Microscopy and Gene Expression Studies (2002) (398)
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa (1980) (397)
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. (1973) (394)
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. (1995) (393)
Inhibition of prostaglandin biosynthesis. (1974) (386)
Prostacyclin is a circulating hormone (1978) (381)
Prostacyclin (PGX) is the endogeneous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid (1977) (381)
Co‐induction of nitric oxide synthase and cyclo‐oxygenase: interactions between nitric oxide and prostanoids (1995) (364)
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. (1993) (361)
Mechanism of action of antiinflammatory drugs. (1998) (337)
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. (1978) (337)
Induction of cyclo‐oxygenase‐2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone (1994) (331)
Mediators Produced by the Endothelial Cell (1988) (330)
THE USE OF ISOLATED ORGANS FOR DETECTING ACTIVE SUBSTANCES IN THE CIRCULATING BLOOD (1997) (329)
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. (1991) (326)
Prostaglandins, Aspirin-like Drugs and the Oedema of Inflammation (1973) (317)
Mechanism of action of anti-inflammatory drugs. (1997) (317)
PHOSPHOLIPASE A2 ACTIVITY OF GUINEA‐PIG ISOLATED PERFUSED LUNGS: STIMULATION, AND INHIBITION BY ANTI‐INFLAMMATORY STEROIDS (1978) (314)
Prostaglandins and the mechanism of analgesia produced by aspirin‐like drugs (1997) (311)
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. (1989) (305)
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. (1997) (304)
The role of prostacyclin in vascular tissue. (1979) (304)
Pharmacodynamic profile of prostacyclin. (1995) (301)
Imidazole: a selective inhibitor of thromboxane synthetase. (1977) (301)
Endothelin‐1 and Endothelin‐3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit (1989) (300)
Fate of Angiotensin I in the Circulation (1968) (299)
Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. (1993) (292)
Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. (1978) (292)
COMPARISON OF THE VASODEPRESSOR EFFECTS OF PROSTACYCLIN AND 6‐OXO‐PROSTAGLANDIN F1α WITH THOSE OF PROSTAGLANDIN E2 IN RATS AND RABBITS (1978) (278)
The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications. (1983) (275)
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. (1988) (272)
International Union of Pharmacology nomenclature of endothelin receptors. (1994) (268)
The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. (1980) (251)
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. (1988) (250)
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. (1989) (248)
The mode of action of aspirin and similar compounds. (1976) (244)
THE DISTRIBUTION AND METABOLISM OF ARACHIDONIC ACID IN RABBIT PLATELETS DURING AGGREGATION AND ITS MODIFICATION BY DRUGS (1977) (242)
Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. (1975) (228)
The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase (1995) (226)
Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock (1995) (225)
Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. (1994) (214)
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea‐pig lungs (1973) (214)
Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. (1987) (211)
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. (1967) (210)
Nociception in cyclooxygenase isozyme-deficient mice. (2000) (208)
Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock (1993) (202)
An analysis of the responses of the isolated stomach to electrical stimulation and to drugs (1963) (201)
The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. (1991) (193)
Pharmacokinetic function of the pulmonary circulation. (1974) (192)
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. (1990) (191)
Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide (1990) (190)
Use of the endothelin antagonists BQ‐123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF (1993) (190)
History of Aspirin and Its Mechanism of Action (1990) (188)
The contribution of prostaglandin production to contractions of the isolated uterus of the rat (1973) (187)
Activity of Various Fractions of Bradykinin Potentiating Factor against Angiotensin I Converting Enzyme (1970) (186)
Prostaglandins, oxygen tension and smooth muscle tone (1972) (180)
Prostaglandins, their intermediates and precursors: cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. (1979) (178)
Mechanism of action of aspirin-like drugs. (1997) (174)
Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. (1994) (168)
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. (1976) (166)
A SENSITIVE METHOD FOR THE ASSAY OF ANGIOTENSIN. (1964) (165)
Metabolism of the Angiotensins in Isolated Perfused Tissues (1969) (164)
The Fate of Radioiodinated Endothelin‐1 and Endothelin‐3 in the Rat (1989) (164)
Mechanism of action of anti-inflammatory drugs. (1996) (163)
Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. (1978) (155)
RECIRCULATION OF PROSTACYCLIN (PGI2) IN THE DOG (1978) (155)
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. (1999) (154)
Release of Prostaglandin E1 from the Rat Stomach (1967) (153)
Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. (1979) (152)
Inhibition of cyclo-oxygenase and lipoxygenase. (1983) (152)
Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. (1993) (150)
Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. (1990) (150)
Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro. (1978) (150)
Dependence of Bone Marrow Cells on the Liver for Purine Supply (1958) (148)
Superoxide anions enhance platelet adhesion and aggregation (1989) (147)
5-Hydroxytryptamine in the Circulation of the Dog (1967) (146)
Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. (1995) (145)
The technique of superfusion (1997) (144)
An analysis of the direct and indirect actions of drugs on the isolated guinea-pig ileum. (1963) (144)
Disappearance of Angiotensin from the Circulation of the Dog (1967) (142)
The fight against rheumatism: from willow bark to COX-1 sparing drugs. (2000) (142)
Contribution of Intrarenal Generation of Prostaglandin to Autoregulation of Renal Blood Flow in the Dog (1973) (140)
Eicosanoids in inflammation. (1984) (140)
An excitatory nociceptive cardiac reflex elicited by bradykinin and potentiated by prostaglandins and myocardial ischaemia. (1976) (138)
Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors (1993) (137)
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat (1993) (136)
Possible Contributions of Endogenous Prostaglandins to the Control of Blood Pressure (1975) (134)
The Discovery of Captopril (2003) (133)
Effects on Smooth Muscle Preparations of Unidentified Vasoactive Peptides from Intestine and Lung (1970) (128)
Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen (1973) (124)
Kinins act on B1 or B2 receptors to release conjointly endothelium‐derived relaxing factor and prostacyclin from bovine aortic endothelial cells (1989) (124)
Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids (1976) (123)
Synthesis of 6-keto-PGF1a by ram seminal vesicle microsomes (1977) (123)
The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. (1959) (120)
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. (1990) (120)
Vascular actions of arachidonic acid and its metabolites in perfused mesenteric and femoral beds of the dog. (1978) (120)
Nitric Oxide: A Regulatory Mediator of Mast Cell Reactivity (1991) (119)
The Effect of Prostacyclin (PGI2) on Platelet Behaviour. Thrombus Formation in Vivo and Bleeding Time (1979) (119)
The effects of alteration of blood‐volume on the concentration of circulating angiotensin in anaesthetized dogs (1966) (119)
Prostacyclin: a vascular mediator. (2003) (119)
An analysis of the responses of the isolated portal vein of the rabbit to electrical stimulation and to drugs. (1967) (117)
A better understanding of anti-inflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). (1995) (116)
Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. (1980) (115)
Prostacyclin: its biosynthesis, actions, and clinical potential. (1981) (114)
Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits. (1992) (113)
Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. (1976) (113)
Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. (1977) (110)
Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. (1995) (108)
Biosynthesis of prostaglandin (PGI2) and 12L-hydroxy-5,8,10,14-eicosatetraenoic acid (HETE) by pericardium, pleura, peritoneum and aorta of the rabbit. (1979) (107)
The Renin–Angiotensin System: Inhibition of Converting Enzyme in Isolated Tissues (1970) (107)
The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S). (1977) (105)
PROSTACYCLIN CAN REPLACE HEPARIN IN HÆMODIALYSIS IN DOGS (1978) (105)
Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism (1976) (105)
Half-lives of Peptides and Amines in the Circulation (1967) (104)
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti‐inflammatory drugs (1972) (104)
The involvement of endothelium‐derived relaxing factor in the regulation of renal cortical blood flow in the rat (1991) (103)
Anoxia‐Induced Release of Prostaglandins in Rabbit Isolated Hearts (1975) (103)
Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. (1995) (100)
The release of catecholamines from the adrenal medulla by peptides. (1967) (99)
Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. (1995) (97)
The release of catechol amines from the adrenal medulla by histamine. (1965) (96)
Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. (1978) (96)
Nitroxergic nerves mediate vagally induced relaxation in the isolated stomach of the guinea pig. (1991) (96)
Structural requirements for opioid activity of analogues of the enkephalins (1977) (95)
Introduction: mechanism of action of NSAIDs. (1996) (94)
Some Properties of Angiotensin Converting Enzyme in the Lung in vivo (1970) (94)
Involvement of tyrosine kinase in the induction of cyclo‐oxygenase and nitric oxide synthase by endotoxin in cultured cells (1994) (93)
Support of renal blood flow after ischaemic‐reperfusion injury by endogenous formation of nitric oxide and of cyclo‐oxygenase vasodilator metabolites (1993) (92)
Mode of Action of Anti-Inflammatory Agents Which are Prostaglandin Synthetase Inhibitors (1979) (92)
Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes. (1975) (91)
The mode of action of anti-inflammatory drugs. (1990) (91)
Aspirin and Other Salicylates (1993) (91)
Endothelins come home to roost (1990) (90)
Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase (1991) (90)
Endothelin‐1 Releases Eicosanoids from Rabbit Isolated Perfused Kidney and Spleen (1989) (90)
Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1α in the rat paw (1978) (90)
Incomplete inhibition of the pressor effects of endothelin‐1 and related peptides in the anaesthetized rat with BQ‐123 provides evidence for more than one vasoconstrictor receptor (1993) (89)
PROSTACYCLIN: A SOLUTION TO SOME PROBLEMS OF EXTRACORPOREAL CIRCULATION Experiments in Greyhounds (1979) (89)
Cytokine‐mediated induction of cyclo‐oxygenase‐2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide (1995) (89)
Cultured endothelial cells maintain their L-arginine level despite the continuous release of EDRF. (1990) (88)
Prostaglandins and the Aspirin-Like Drugs (1972) (88)
Back to an Aspirin a Day? (2002) (87)
Prostaglandins and the cardiovascular system. (1983) (87)
Cytokine Regulation of Endothelin‐1 Release from Bovine Aortic Endothelial Cells (1995) (86)
Release of Catecholamines in the Guinea-pig by Substances involved in Anaphylaxis (1967) (83)
Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. (1992) (83)
Disappearance of Catecholamines from the Circulation (1968) (83)
Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. (1993) (82)
Pain and Inflammatory Mediators (1978) (81)
Endothelin‐1 Releases Prostacyclin and Inhibits ex vivo Platelet Aggregation in the Anesthetized Rabbit (1989) (81)
THE DISCOVERY OF PROSTACYCLIN – – – A FRESH INSIGHT INTO ARACHIDONIC ACID METABOLISM (1977) (79)
Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. (1993) (78)
The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation. (1994) (78)
Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme. (1973) (78)
Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. (1983) (77)
Modification of basal release of prostaglandins from rabbit isolated hearts. (1974) (76)
Prostaglandins in the saliva of the cattle tick, Boophilus microplus (Canestrini) (Acarina, Ixodidae) (1976) (75)
Adventures and excursions in bioassay: the stepping stones to prostacylin (1983) (75)
The detection and estimation of bradykinin in the circulating blood. (1967) (75)
Pharmacology of Endothelin‐1 in Isolated Vessels: Effect of Nicardipine, Methylene Blue, Hemoglobin, and Gossypol (1989) (74)
The endothelial cell as a metabolic and endocrine organ (1987) (73)
Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: requirement of a serum factor (1994) (73)
Hormones released into the circulation when the urinary bladder of the anaesthetized dog is distended. (1971) (73)
Improved Non-Steroid Anti-Inflammatory Drugs: COX-2 Enzyme Inhibitors (1996) (73)
Gastric secretion induced by histamine and its relationship to the rate of blood flow (1953) (71)
The continuous estimation of angiotensin formed in the circulation of the dog (1966) (71)
On the substrate specificity of nitric oxide synthase (1991) (70)
Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line. (1992) (69)
Reversal of established responses to endothelin‐1 in vivo and in vitro by the endothelin receptor antagonists, BQ‐123 and PD 145065 (1994) (68)
Glibenclamide‐induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat (1995) (68)
Overview — mechanisms of action of anti-inflammatory drugs (1996) (68)
Prostacyclin (PGI2) induces coronary vasodilatation in anaesthetised dogs. (1978) (68)
Inhibition of Converting Enzyme of the Renin‐Angiotensin System in Kidneys and Hindlegs of Dogs (1972) (67)
Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis. (1978) (67)
PROSTAGLANDIN PRODUCTION BY RABBIT ISOLATED JEJUNUM AND ITS RELATIONSHIP TO THE INHERENT TONE OF THE PREPARATION (1976) (65)
Nitric oxide and another potent vasodilator are formed from NG-hydroxy-L-arginine by cultured endothelial cells. (1991) (65)
Prostacyclin in the cardiovascular system. (1980) (65)
Biotransformation and cardiovascular effects of arachidonic acid in the dog. (1979) (64)
Evidence from receptor antagonists of an important role for ETB receptor‐mediated vasoconstrictor effects of endothelin‐1 in the rat kidney (1994) (64)
Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. (1993) (63)
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins (1972) (63)
Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat (1996) (62)
Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. (1993) (62)
Prostacyclin (PGI2) is a weak contractor of coronary arteries of the pig. (1977) (61)
SOME DIRECT AND REFLEX CARDIOVASCULAR ACTIONS OF PROSTACYCLIN (PGI2) AND PROSTAGLANDIN E2 IN ANAESTHETIZED DOGS (1980) (60)
The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion (1994) (60)
NSAIDs, Cox-2 inhibitors, and the gut (1995) (60)
Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats (1995) (60)
Endothelin inhibits ex vivo platelet aggregation in the rabbit. (1988) (60)
Effects of prostacyclin and a stable analogue, 6β-PGI1, on gastric acid secretion, mucosal blood flow, and blood pressure in conscious dogs (1979) (59)
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease (1990) (59)
The mechanism of the inhibitory effect of polyamines on the induction of nitric oxide synthase: role of aldehyde metabolites (1994) (59)
The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO‐donors (1990) (59)
Relaxations of the isolated portal vein of the rabbit induced by nicotine and electrical stimulation (1970) (59)
Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin. (1994) (59)
Mast cells as a source of superoxide anions and nitric oxide-like factor: relevance to histamine release. (1991) (58)
Endothelium-derived relaxing factor participates in the increased blood flow in response to pentagastrin in the rat stomach mucosa (1990) (58)
The Evolution of Non-Steroidal Anti-Inflammatory Drugs and their Mechanisms of Action (2012) (58)
The contribution of tumour necrosis factor‐α and endothelin‐1 to the increase of coronary resistance in hearts from rats treated with endotoxin (1995) (58)
Increased Angiotensin Formation in Response to Carotid Occlusion in the Dog (1966) (57)
Synthesis of arachidonate cyclo-oxygenase products by rheumatoid and nonrheumatoid synovial lining in nonproliferative organ culture (1983) (56)
Prostacyclin in physiology and pathophysiology. (1982) (56)
Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. (1990) (55)
RAPID REDUCTION OF PROSTAGLANDIN 15‐HYDROXY DEHYDROGENASE ACTIVITY IN RAT TISSUES AFTER TREATMENT WITH PROTEIN SYNTHESIS INHIBITORS (1975) (55)
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. (1977) (55)
Selective inhibition of agonist‐induced but not shear stress‐dependent release of endothelial autacoids by thapsigargin (1993) (53)
Characterization of ETB receptors mediating contractions induced by endothelin‐1 or IRL 1620 in guinea‐pig isolated airways: effects of BQ‐123, FR139317 or PD 145065 (1994) (52)
Prostaglandins as Mediators of Reactive Hyperaemia in Kidney (1974) (52)
Bioassay of prostaglandins and biologically active substances derived from arachidonic acid. (1978) (51)
The cardiac sphincter in the cat (1961) (51)
The relation between the motor and inhibitor actions of acetylcholine (1949) (51)
Further experiments to establish that the analgesic action of aspirin-like drugs depends on the inhibition of prostaglandin biosynthesis. (1973) (51)
Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach (1994) (51)
Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation (1989) (51)
Metabolic Functions of the Lung (1977) (50)
A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs. (1984) (50)
The inactivation of noradrenaline and isoprenaline in dogs (1970) (49)
Adventures and Excursions in Bioassay: The Stepping Stones to Prostacylin (1983) (49)
Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. (1993) (49)
The generation of L-arginine in endothelial cells is linked to the release of endothelium-derived relaxing factor. (1990) (49)
Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. (1991) (49)
ANTITHROMBOTIC PROPERTIES OF VASCULAR ENDOTHELIUM (1977) (49)
The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. (1984) (49)
PROSTACYCLIN (PGI2) INHIBITS THE FORMATION OF PLATELET THROMBI IN ARTERIOLES AND VENULES OF THE HAMSTER CHEEK POUCH (1978) (49)
Therapeutic Roles Of Selective Cox-2 Inhibitors (2001) (49)
Endothelin‐1 inhibits platelet aggregation in vivo: a study with 111indium‐labelled platelets (1990) (49)
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. (1972) (47)
The continuous bioassay of the release and disappearance of histamine in the circulation (1973) (46)
Inhibition by l‐glutamine of the release of endothelium‐derived relaxing factor from cultured endothelial cells (1990) (46)
Endothelin-1 contracts isolated vessels independently of dihydropyridine-sensitive Ca2+ channel activation. (1989) (45)
Prostacyclin is produced in whole blood [proceedings]. (1978) (45)
Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP‐sensitive potassium channels (1995) (45)
Adventures and Excursions in Bioassay: The Stepping Stones to Prostacyclin (Noble Lecture) (1983) (45)
Effects of oxygen tension on vascular and other smooth muscle (1966) (45)
Conversion of glyceryl trinitrate to nitric oxide in tolerant and non‐tolerant smooth muscle and endothelial cells (1993) (45)
Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C. (1984) (44)
Prostacyclin release induced by bradykinin may contribute to the antihypertensive action of angiotensin-converting enzyme inhibitors. (1980) (44)
The Hemodynamic Effects of Endothelin‐1 in the Pithed Rat (1989) (43)
Roles of endothelin receptors in the regional and systemic vascular responses to ET‐1 in the anaesthetized ganglion‐blocked rat: use of selective antagonists (1995) (43)
Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion (1989) (42)
Appearance of prostaglandins in the renal venous blood of dogs in response to acute systemic hypotension produced by bleeding or endotoxin. (1973) (42)
An adverse effect of polyvinylchloride tubing used in extracorporeal circulation. (1968) (42)
L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta. (1990) (41)
Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. (1993) (41)
Sodium nitroprusside modulates the fibrinolytic system in the rabbit (1990) (41)
The effects of antiinflammatory drugs on the production of prostaglandins in vivo. (1976) (41)
Prostaglandins and the regulation of blood pressure. (1975) (40)
Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea‐pig ileum (1993) (40)
The two-step conversion of big endothelin 1 to endothelin 1 and degradation of endothelin 1 by subcellular fractions from human polymorphonuclear leukocytes. (1992) (40)
The density flowmeter, a direct method for the measurement of the rate of blood flow (1953) (39)
Time-trends in gastroprotection with NSAIDs (2010) (39)
Biomedicine. Back to an aspirin a day? (2002) (38)
Endothelin‐1 Causes Vasoconstriction and Vasodilation in the Blood Perfused Liver of the Dog (1989) (38)
Localization of [125I]endothelin-1 and [125I]endothelin-3 binding sites in the rat brain. (1989) (37)
An antiserum to 5,6-dihydro prostacyclin (PGI1) which also binds prostacyclin. (1978) (37)
The mode of action of aspirin-like drugs (1978) (37)
Prostaglandins and thromboxanes from fatty acids. (1986) (37)
Formation by the endothelium of prostacyclin, nitric oxide and endothelin. (1993) (36)
Different patterns of release of endothelium‐derived relaxing factor and prostacyclin (1992) (36)
Endothelins release tissue plasminogen activator and prostanoids. (1990) (36)
Inhibition of the production of nitric oxide and vasodilator prostaglandins attenuates the cardiovascular response to bacterial endotoxin in adrenalectomized rats (1993) (36)
Short term suppression of hyperacute renal allograft rejection in presensitised dogs with prostacyclin. (1980) (36)
Biological significance and therapeutic potential of prostacyclin. (1980) (35)
Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin (1992) (35)
Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators (1990) (35)
Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine (1991) (35)
Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. (1982) (34)
The history of inhibitors of angiotensin converting enzyme. (1999) (34)
Role of intracellular thiols in release of EDRF from cultured endothelial cells. (1992) (34)
Proceedings: Potentiation by prostaglandins of the nociceptive activity of bradykinin in the dog knee joint. (1974) (34)
The role of prostaglandins in the local control of circulation. (1975) (34)
Release of prostaglandin E-1 from the rat stomach. (1967) (33)
Prostaglandin production contributes to the contractions of the rat isolated uterus. (1972) (33)
A sensitive method for the assay of 5‐hydroxytryptamine (1997) (33)
The relationship between the penetration of tryptamine and 5-hydroxytryptamine into smooth muscle and the associated contractions. (1967) (33)
Therapeutic Applications of Prostaglandins (1993) (33)
PROSTACYCLIN FORMATION AND EFFECTS (1979) (33)
Interactions between bradykinin and prostaglandins (1975) (33)
Prostacyclin: homeostatic regulator or biological curiosity? (1981) (33)
Impaired prostaglandin release from the kidneys of salt-loaded and hypertensive rats. (1974) (32)
Secretory functions of the vascular endothelium. (1992) (32)
Evidence for vesicles that transport endothelin-1 in bovine aortic endothelial cells. (1993) (32)
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. (1976) (32)
A SENSITIVE METHOD FOR THE ASSAY OF CATECHOL AMINES. (1964) (32)
Disappearance of prostacyclin (PGI2) in the circulation of the dog [proceedings]. (1978) (32)
The Fate of Angiotensin I (1974) (31)
Prostacyclin and its clinical applications. (1984) (31)
The history of anti-inflammatory drugs and their mechanism of action (1996) (31)
Aspirin and Prostaglandins (1974) (30)
Effects of Gastrin and its Analogues on Isolated Smooth Muscles (1967) (30)
Characterization of endothelin (ET) receptors in the isolated gall bladder of the guinea‐pig: evidence for an additional ET receptor subtype (1994) (30)
Microcirculatory effects of prostacyclin (PGI2) in the hamster cheek pouch. (1979) (30)
Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin. (1983) (29)
Release of renal prostaglandins during endotoxin-induced hypotension. (1976) (29)
Prostacyclin (PGI2), the Vascular Wall and Vasodilatation (1978) (29)
FMRF-amide and L-Arg-L-Phe increase blood pressure and heart rate in the anaesthetised rat by central stimulation of the sympathetic nervous system. (1991) (29)
Genetic engineering and pharmaceuticals (1984) (28)
Tetrahydrobiopterin synthesis is induced by LPS in vascular smooth muscle and is rate-limiting for nitric oxide production. (1993) (28)
Mediation of endothelin‐1‐induced inhibition of platelet aggregation via the ETB receptor (1993) (28)
Alkaline buffers release EDRF from bovine cultured aortic endothelial cells (1991) (28)
Regulatory mechanisms of the vascular endothelium: an update. (1994) (27)
Cultured astrocytoma cells inhibit platelet aggregation by releasing a nitric oxide-like factor. (1990) (27)
Eicosanoids, Aspirin, and Asthma (1998) (27)
Regional Vascular Resistance and Haemodynamics in the Spontaneously Hypertensive Rat: The Effects of Bradykinin (1990) (27)
Endothelin-3: selectivity as an anti-aggregatory peptide in vivo. (1989) (27)
Rabbit-aorta contracting substance (RCS) may be a prostaglandin precursor. (1971) (27)
Proceedings: the concomitant release of bradykinin and prostaglandin in the inflammatory response to carrageenin. (1974) (27)
Nitric oxide and hypertension. (1996) (27)
The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. (1970) (27)
Cardiovascular actions of prostacyclin (PCI2) in chloralose anaesthetized dogs [proceedings]. (1977) (27)
B. THE ESTIMATION OF CATECHOLAMINES BY BIOLOGICAL ASSAY (1966) (26)
Effects of phosphoramidon in endothelial cell cultures on the endogenous synthesis of endothelin-1 and on conversion of exogenous big endothelin-1 to endothelin-1. (1993) (26)
Simultaneous measurement of endothelium‐derived relaxing factor by bioassay and guanylate cyclase stimulation (1989) (26)
Lipopolysaccharide increases release of a nitric oxide-like factor from endothelial cells. (1989) (26)
Tryptamines and spinal cord reflexes in cats. (1967) (26)
Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research (1997) (24)
Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. (1991) (24)
Endothelin‐1 Mediates Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines (1995) (24)
Cultured astrocytoma cells generate a nitric oxide‐like factor from endogenous L‐arginine and glyceryl trinitrate: effect of E. coli lipopolysaccharide (1992) (24)
MODE OF ACTION OF BENOXAPROFEN (1984) (24)
Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065. (1993) (24)
Inhibition of uterine motility: the possible role of the prostaglandins and aspirin-like drugs. (1975) (24)
Purity and Stability of Synthetic Peptides such as Angiotensins and Kinins (1971) (24)
[Perspectives in science]. (1977) (23)
Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice. (1997) (23)
Role for intracellular platelet‐activating factor in the circulatory failure in a model of Gram‐positive shock (1995) (23)
The relative activity of prostacyclin (PGI2) and a stable analogue 6β‐PGI1 on the gastrointestinal and cardiovascular systems (1978) (23)
Mediators and the anti-thrombotic properties of the vascular endothelium. (1989) (23)
Superoxide Dismutase Cooperates with Prostacyclin to Inhibit Platelet Aggregation: a Comparative Study in Washed Platelets and Platelet Rich Plasma (1991) (22)
Control of the Circulation by Endothelial Mediators (1993) (22)
Some Cardiovascular Properties of Prostacyclin (PGI2) Which Are Not Shared by PGE2 (1980) (22)
Prostacyclin in the Cardiovascular System in Health and Disease (1985) (22)
The endothelial cell in health and disease (1995) (22)
Relative potency of prostacyclin, prostaglandin E1 and D2 as inhibitors of platelet aggregation in several species [proceedings]. (1977) (22)
The effects of endothelium‐dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside (1988) (21)
Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch (1997) (21)
Elimination of prostacyclin (PGI2) and 6‐oxo‐PGF1α in anaesthetized dogs (1979) (21)
Biological Sciences: Blood Concentration of Noradrenaline in the Dog after Intravenous Administration and the Effects of Desipramine (1971) (21)
Role of the Vagus Nerve in the Control of the Concentration of Angiotensin II in the Circulation (1969) (21)
Impairment of the L-arginine-nitric oxide pathway in mast cells from spontaneously hypertensive rats. (1991) (21)
Prostacyclin as a potent dilator of arterioles in the hamster cheek pouch [proceedings]. (1978) (21)
Human polymorphonuclear leukocytes generate and degrade endothelin-1 by two distinct neutral proteases. (1991) (21)
The mechanism of action of anti-inflammatory drugs. (2003) (21)
The generation of kinins in the blood of dogs during hypotension due to haemorrhage. (1970) (21)
Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. (1995) (20)
Endothelins: potent releasers of prostacyclin and EDRF. (1990) (20)
Radioimmunoassay evidence that the pressor effect of big endothelindash1 is due to local conversion to endothelindash1 (1995) (20)
Formation of prostacyclin (PGl2) by different layers of the arterial wall. (1977) (20)
The mechanism of action of anti-inflammatory drugs. (2003) (20)
Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols. (1991) (19)
The future of NSAID therapy: selective COX‐2 inhibitors (2000) (19)
Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. (1995) (19)
The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats (1994) (19)
EXPERIMENTAL ASSESSMENT OF PROSTACYCLIN IN THE HARVESTING OF KIDNEYS FOR TRANSPLANTATION (1980) (19)
The metabolism of glyceryl trinitrate to nitric oxide in the macrophage cell line J774 and its induction by Escherichia coli lipopolysaccharide. (1992) (19)
Sites of Conversion of Angiotensin I (1972) (19)
Implications of prostacyclin generation for modulation of vascular tone. (1978) (18)
Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. (1994) (18)
Prostacyclin can Replace Heparin for Haemodialysis in Dogs (1979) (18)
Effect of indomethacin on endotoxin-induced production of prostaglandins in the isolated rabbit jejunum. (1976) (18)
3 – Biological Properties of Cyclooxygenase Products (1994) (17)
The refractory period of atria isolated from mammalian hearts (1956) (17)
Letter: Reduction of the inflammatory response in rats immunized against prostaglandins. (1974) (17)
Endothelium-derived vasoactive factors and the control of the circulation. (1991) (17)
Effect of Captopril on the bradykinin‐induced release of prostacyclin from guinea‐pig lungs and bovine aortic endothelial cells (1988) (17)
Potentiation of the vasorelaxant activity of nitric oxide by hydroxyguanidine: implications for the nature of endothelium‐derived relaxing factor (1992) (17)
Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. (1994) (17)
Comparison of the release of vasoactive factors from venous and arterial bovine cultured endothelial cells. (1992) (17)
The endothelin ETB receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. (1994) (16)
The anti-thrombotic effects of prostacyclin. (2009) (15)
PROSTACYCLIN (PGI2) INHIBITS THE FORMATION OF PLATELET THROMBI IN ARTERIOLES AND VENULES OF THE HAMSTER CHEEK POUCH (1997) (15)
Studies on the importance of the proposed release of nitric oxide from platelets. (1991) (15)
Clinical potential of prostacyclin. (1983) (15)
The effects of histamine on the plasma potassium levels of cats. (1956) (15)
Dissociation of the anti‐ischaemic effects of cloricromene from its anti‐platelet activity (1993) (15)
A sensitive and specific assay for vasopressin in the circulating blood (1970) (15)
Prostacyclin-release by bradykinin in vivo [proceedings]. (1979) (15)
Concurrent Measurement of Renin and Angiotensin in the Circulation of the Dog (1967) (14)
Interrelationships between prostacyclin and thromboxane A2. (2008) (14)
Prostacyclin-sensitive adenylate cyclase in cultured myocytes: differences between rabbit aorta and mesenteric artery. (1984) (14)
NG-hydroxy-L-arginine and hydroxyguanidine potentiate the biological activity of endothelium-derived relaxing factor released from the rabbit aorta. (1992) (14)
Fibrinolytic activity of endothelin-3. (1989) (14)
Biological Activities of Some Metabolites and Analogues of Prostacyclin (1981) (14)
1-n-Butylimidazole: a potent and selective inhibitor of 'thromboxane synthetase' [proceedings]. (1978) (14)
Release of vaso-active substances from lungs by injection of particles. (1970) (14)
Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation. (1978) (14)
Endotoxin and production of prostaglandins by the isolated rabbit jejunum. Influence of indomethacin. (1975) (14)
Prostacyclin and the vascular endothelium. (1981) (13)
Mechanism of action of anti-inflammatory drugs: an overview (1998) (13)
The role of chemical mediators released by the endothelium in the control of the cardiovascular system. (1992) (13)
Mediators from the endothelial cell and their participation in inflammation. (1994) (13)
Trumping the ACE (1995) (13)
Prostaglandins and the mechanism of analgesia produced by aspirin‐like drugs (1973) (13)
Calcium ionophores inhibit the release of endothelin-1 from endothelial cells. (1993) (13)
Anti-Inflammatory Drugs and the Arachidonic Acid Cascade (1987) (13)
The National Religious Environment and the Orthodoxy of Christian Beliefs: A Comparison of Austria, the Czech Republic and Slovakia (2013) (13)
The Role of Prostaglandins in Platelet-Vessel Wall Interactions (1982) (12)
Proceedings: Formation of prostaglandin endoperoxides and rabbit aorta contracting substance (RCS) by coupling two enzyme systems. (1976) (12)
NG‐hydroxy‐L‐arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat (1992) (12)
Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. (1994) (12)
Characterization of Serine Protease‐Derived Metabolites of Big Endothelin in the Cytosolic Fraction from Human Polymorphonuclear Leukocytes (1992) (12)
Prostacyclin and Blood Coagulation (1981) (12)
Gastric secretion induced by histamine (1953) (12)
Inhibition of platelet-derived mitogen release by nitric oxide (EDRF) (1989) (12)
Rat mast cells inhibit platelet aggregation by releasing a nitric oxide-like factor: influence of histamine release. (1991) (11)
Arachidonic acid metabolism in inflammation and the mode of action of anti-inflammatory drugs. (1979) (11)
843 - REDUCTION OF LEUKOCYTE MIGRATION BY A CYCLO-OXYGENASE AND LIPOXYGENASE INHIBITOR (1978) (11)
Characterization of a Microsomal Calcium‐Dependent Nitric Oxide Synthase in Activated J774.2 Monocyte/Macrophages (1992) (11)
The release of catecholamines by shocks and stimuli paired with shocks. (1969) (11)
Prostacyclin (PGI2) inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo [proceedings]. (1977) (10)
Mechanisms of the Endothelium‐Dependent Relaxation Induced by NG‐Hydroxy‐L‐Arginine (1992) (10)
Mode of action of aspirin-like drugs. (1979) (10)
Fate of prostaglandins in the lungs. (1969) (10)
Interaction between anti-inflammatory drugs and inflammatory mediators. A reference to products of arachidonic acid metabolism. (1977) (10)
The assay of catecholamines released into the circulation of the guinea-pig by angiotensin. (1967) (10)
The receipt and dispatch of chemical messengers by endothelial cells. (1989) (10)
Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1. (1996) (10)
Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1. (1995) (10)
Prostacyclin production by rabbit aorta, pericardium, pleura, peritoneum and dura mater. (1978) (10)
The Discovery of Captopril: a reply (2004) (10)
Prostacyclin eliminates the thrombocytopenia associated with charcoal hemoperfusion and minimizes heparin and fibrinogen consumption. (1980) (10)
Prostaglandin X, the vascular metabolite of arachidonic acid responsible for relaxation of bovine coronary artery strips [proceedings]. (1977) (10)
The actions of endothelins−1 and −3 on the vascular and capsular smooth muscle of the isolated blood perfused spleen of the dog (1992) (10)
COX-2 inhibitors: background knowledge for clinical use. Introduction. (1998) (10)
Control of the circulation by vasoactive mediators from endothelial cells. (1994) (9)
Heterogeneous receptors mediate endothelin-1-induced changes in blood pressure, hematocrit, and platelet aggregation. (1993) (9)
Sites of uptake of3H-5-hydroxytryptamine in rat isolated lung (1974) (9)
Cyclo-oxygenase-2 inhibitors and cardiovascular events (2002) (9)
AGENDA-SETTING EFFECT OF FOCUSING EVENTS: A CASE STUDY OF THE CHURCH RESTITUTIONS ISSUE (2013) (9)
THE STRUCTURE OF PROSTAGLANDIN I 2 (1977) (9)
Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. (1990) (9)
Adventures and excursions in bioassay: the stepping stones to prostacyclin. Nobel Lecture, 8 December 1982. (1983) (8)
Does Prostaglandin Release Contribute to the Hypotension Induced by Inhibitors of Angiotensin Converting Enzyme (1983) (8)
Selective proteolitic activation and degradation of ETs and big ETs in parenchymal strips of the guinea-pig lung. (1995) (8)
Vasoactive mediators derived from the endothelium. (1989) (8)
A new perfusion method (1953) (8)
Heart disease, aspirin, and fish oil. (1991) (8)
Antagonism of renal and systemic responses to endothelin-1 infusion with PD 145065. (1994) (8)
The conversion of angiotensin I to angiotensin II in vivo (2004) (8)
Prostacyclin reduces the number of 'slow moving' leucocytes in hamster cheek pouch venules [proceedings]. (1978) (8)
Inhibition of the release of endothelium‐derived relaxing factor in vitro and in vivo by dipeptides containing NG‐nitro‐l‐arginine (1991) (8)
The release and assay of hormones in the circulation. (1968) (8)
Blood concentrations of adrenaline in dogs after intravenous administration of 5-hydroxytryptamine. (1972) (8)
The Role of the Endothelium in Vascular Homeostasis (1990) (7)
The estimation of catecholamines by biological assay. (1966) (7)
Effect of prostacyclin on myogenic activity and adrenergic neuroeffector interaction in isolated canine veins. (1978) (7)
The quantitative determination of diffusible histamine in blood. (1952) (7)
The use of isolated organs for detecting active substances in the circulating blood (1997) (7)
Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1alpha in the rat paw. (1978) (7)
Comparison of the survival of endothelium‐derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat (1989) (7)
My life and times with enzymes and mediators. (2001) (7)
The effect of venous occlusion on arterial blood flow in the extremities; an experimental study. (1952) (7)
RECIRCULATIONOF PROSTACYCLIN(PGI2)INTHE DOG (1978) (7)
Mediators from the endothelial cell. (1991) (7)
Lack of Effect of ET Antibody or SB 209670 on Endotoxin‐Induced Renal Failure (1995) (7)
Interaction of the effects of tyramine, amphetamine and reserpine in man (1962) (7)
Experimental Studies of Gastric Blood Flow: Preliminary Report (1952) (7)
The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1. (1995) (6)
Formation of prostacyclin and its product 6-oxo-PGF1alpha by the gastric mucosa of several species [proceedings]. (1978) (6)
Proceedings: Inhibition of the pulmonary inactivation of prostaglandins in rabbit in vivo. (1975) (6)
Endothelin-1 and big endothelin cause subarachnoid hemorrhage in the anesthetized rabbit. (1991) (6)
Inhibitory effects of aprotinin on kallikrein and kininases in dog's blood (1971) (6)
Unstable Metabolites of Arachidonic Acid in Relation to Thrombosis (1979) (6)
Study of the mechanisms of the modifying actions of hexamethonium on the cardiovascular response to norepinephrine. (1973) (6)
The road to prostacyclin. (1985) (6)
Nitroblue tetrazolium inhibits oxidation of glyceryl trinitrate to nitric oxide in bovine aortic smooth muscle cells. (1994) (6)
Biotransformation of arachidonic acid in the circulation of the dog [proceedings]. (1978) (6)
An improved method for the extraction of prostaglandins. (1973) (6)
Prostacyclin : new perspectives for basic research and novel therapeutic indications : proceedings of the Symposium on Novel Perspectives in Prostacyclin Research, Vienna, Austria, 25th September 1991 (1992) (6)
The blockade of the local generation of prostaglandins explains the analgesic action of aspirin (1973) (5)
byactivation oftyrosine kinase inbovine endothelial cells stimulated by bacterial lipopolysacchari de (1995) (5)
ET touches down in Houston (1993) (5)
Purification and properties of arachidonate-15-lipoxygenase from rabbit peritoneal polymorphonuclear leukocytes. (1982) (5)
The biosynthesis of endothelium-derived relaxing factor by endothelial cells as a means of removing excess nitrogen (1991) (5)
Some properties of rabbit aorta contracting substance-releasing factor (RCS-RF) [proceedings]. (1976) (5)
Contractile activity of endothelin precursors in the isolated gallbladder of the guinea‐pig: presence of an endothelin‐converting enzyme (1995) (5)
Antagonism of Bradykinin Bronchoconstriction by Anti-Inflammatory Drugs (1979) (5)
Platelets, acute inflammation and inflammatory mediators (1976) (5)
Polyunsaturated fatty acids as precursors of prostaglandins. (1979) (5)
Some pharmacological actions of paludrine. (1949) (5)
Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670 (1995) (5)
The Pharmacology and Clinical Potential of Prostacyclin (1980) (5)
5‐HT3 receptors do not mediate vagally‐induced relaxation or contraction of the isolated stomach of the guinea‐pig (1994) (5)
The inhibitory action of paludrine on the secretion of gastric juice. (1948) (5)
869 – STIMULATION OF RENIN RELEASE BY PROSTACYCLIN (PGI2) IN ANAESTHETIZED DOGS (1978) (5)
Generation of thromboxane A2-like activity from prostaglandin endoperoxides by polymorphonuclear leukocyte homogenates [proceedings]. (1976) (5)
Traditional and Alternative Religiosity in Contemporary Czech Republic: A Comparison of Age Groups (2010) (4)
A vagal reflex contributes to the hypotensive effect of prostacyclin in anaesthetized dogs [proceedings]. (1978) (4)
The Czech Catholic Church and Problem Legitimation: From Inspiration to Personal Effort (2011) (4)
Factors influencing the turnover of prostaglandin synthetase. (1975) (4)
Drugs that modulate prostaglandins, prostacyclin, and thromboxane A2. (1982) (4)
The potentiation of the cardiovascular responses of the dog to noradrenaline by desmethylimipramine. (1970) (4)
Control of the circulation by endothelial mediators. Inaugural G.B. West Memorial Lecture. (1993) (4)
The influence of pH on aggregation of human washed platelets induced by thrombin or collagen. (1990) (4)
Effects of prostacyclin and a stable analogue, 6-beta-PGI1, on gastric acid secretion, mucosal blood flow, and blood pressure in conscious dogs. (1979) (4)
Effect of venous occlusion on peripheral arterial blood-flow. (1951) (4)
Some effects of d-amphetamine on the behavior of pigeons under intermittent reinforcement (2004) (4)
A possible role of endothelial vasorelaxants in the pathogenesis of migraine (1990) (3)
A sensitive method for the assay of oxytocin in blood. (1970) (3)
The Agenda-Setting Effect of Focusing Events: A Case Study (2013) (3)
NG-monomethyl-L-arginine but not Nω-nitro-L-arginine is metabolized by endottielial cells to L-citrulline (1990) (3)
Endothelin‐1 Mediates the Increase in Ex Vivo Coronary Vascular Resistance Induced by Hemorrhagic Shock in the Anesthetized Rat (1995) (3)
The Actions of Sympathomimetic Amines on Tryptamine Receptors (2008) (3)
Finding the resources to fight tropical disease (1979) (3)
Biosynthesis and function of prostacyclin (PGX) in the heart (1977) (3)
Clinical pharmacology in the pharmaceutical industry. (1991) (3)
The role of circulating catecholamines in arterial baroceptor reflexes in the dog and in man. (1969) (3)
Up-to-date on endothelins (1995) (3)
On the mechanism of the release of prostaglandins E2 and F2 alpha in renal venous blood during endotoxin-hypotension. (1974) (3)
Prostaglandins and the mechanism of analgesia produced by aspirin‐like drugs (1997) (3)
Endothelins: Recent Progress (1995) (2)
The action of choline derivatives on isolated rabbit auricles when arrested by paludrine. (1948) (2)
Metabolic activities of the lung: introduction. (1980) (2)
Reporter's Remarks (1968) (2)
Introduction pharmacokinetic functions of lung (1976) (2)
Nω-nitro-L-arginine (NO2Arg) and NO2Arg-L-phenylalanine inhibit endothelium-dependent vasodilatations in vitro in rabbits and in vivo in the anaesthetized rat (1990) (2)
Meloxicam: A Viewpoint (1996) (2)
Pathways to new drugs. (1985) (2)
[Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation]. (1982) (2)
The dynamics of the renin-angiotensin system (1969) (2)
The metabolism of endothelin-1 and big endothelin-1 by the isolated perfused kidney of the rabbit. (1993) (2)
863 – PROSTACYCLIN (PGI2) PRODUCTION IN THE CAT SPLEEN (1978) (2)
CHAPTER 2 – A Plan for Evaluating Potential Drugs (1964) (2)
Phrmacologic properties of the new nitric oxide donor ITF 296 (1995) (2)
L-glutamine inhibits the generation of L-arginine and the release of endothelium-derived relaxing factor (EDRF) from bovine aortic cultured endothelial cells (1990) (2)
ARACHIDONIC ACID METABOLITES IN THE CARDIOVASCULAR SYSTEM (1981) (2)
PROSTACYCLIN IN HEALTH AND DISEASE (1981) (2)
Prostacyclin 1 (1983) (2)
Prolongation of fibrionolytic activity of tissue plasminogen acitvator by nitorvasodilators (1990) (2)
Phospholipase A2 activity of guinea-pig perfused lungs: stimulation and inhibition by anti-inflammatory steroids [proceedings]. (1977) (2)
Control of the circulation by chemical mediators from the endothelium (1993) (2)
A sensitive method for the assay of 5-hydroxytryptamine (2011) (2)
Ways of Life in the Late Modernity (2013) (2)
Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. (1977) (2)
Prostacyclin: a prostaglandin with therapeutic potential. (1982) (1)
The Biological Importance and Therapeutic Potential of Prostacyclin (1981) (1)
Prostacyclin eliminates the bioincompatibility of charcoal haemoperfusion. (1979) (1)
676 – INCREASED PROSTAGLANDIN PRODUCTION BY TISSUE HOMOGENATES FROM ENDOTOXIN-PRETREATED RABBITS (1977) (1)
L-Arginine transport in endothelial cells (1990) (1)
COMPARISON OF THE INDOCTION PF CYCLO-OXYGENASE AND NITRIC OXIDE SYNTHASE BY ENDOTOXIN IN ENDOTOXIN IN ENDOTHELIAL CELLS AND MACROPHAGE (1995) (1)
Ischaemia and Reperfusion Enhances the Vasoconstrictor Effects of Endothelin-1 in the Isolated Perfused Heart of the Rat (1993) (1)
The Role of the Lungs in the Metabolism of Vasoactive Substances (1972) (1)
Ciba Foundation Symposium jointly with Committee for Symposia on Drug Action on Adrenergic Mechanisms : [Papers and discussions] (1960) (1)
The evolution of ideas in prostaglandin research. (1980) (1)
Comparison of the Haemodynamic and Platelet-Inhibitory Effects of Endothelin-1 and Endothelin-3 in the Anaesthetized Rabbit1 (1990) (1)
NG-Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts (1995) (1)
868 – PROSTACYCLIN (PGI2) AND ARACHIDONIC ACID. BIOTRANSFORMATION IN THE CIRCULATION OF THE DOG (1978) (1)
The Use of Prostacyclin [PGI2) During Charcoal Haemoperfusion (1979) (1)
Potention by veratrine of the responses of isolated vascular tissue to tyramine and sympathetic nerve stimulation (2004) (1)
2170 – PROSTACYCLIN (PGI2) - A SPECIFIC CORONARY DILATING AGENT IN RAT, GUINEA PIG AND RABBIT (1978) (1)
Non-institutionalised Lay Religious Communities in the Czech Republic and the Care for the Ill Strategy (2013) (1)
A SENSITIVE METHOD FOR THE ASSAY OF OXYTOCIN IN THE CIRCULATING BLOOD (1974) (1)
Elimination of prostacyclin (PGI2) and 6-oxo-PGF1 alpha in anaesthetized dogs. (1979) (1)
Effect of prostaglandin E1 and (the NO-donor) isosorbidedinitrate on thromboresistance in human in-vivo. (1990) (1)
Where Is the Sociology of Religion Heading? Some Comments to ‘Three European Sociologies of Religion’ (2008) (1)
The ganglion-blocking properties of hexamethylene bisdialkylsulphonium salts. (1956) (1)
Inflammatory Substances (1973) (1)
The Generation of Kinins in the Circulation of the Dog During Hypotension Due to Blood Loss (1970) (1)
The place of fundamental research in the discovery of new drugs. (1977) (1)
Circulating kinins produced by blood loss in the dog (1969) (1)
Endothelin III : proceedings of the Third International Conference on Endothelin held at the Baylor College of Medicine, Houston, Texas, U.S.A., February 15-17, 1993 (1993) (1)
The distribution of methylpentynol and of methylpentynol carbamate in tissues and body fluids of cats. (1958) (1)
Prostacyclin-release by bradykinin in vivo (2007) (1)
Effects of prostacyclin (PGI2), PGI1 and 6-oxo-PGF1alpha on the rat gastric mucosa [proceedings]. (1978) (1)
Re-addressing relative selectivities. (1997) (1)
Prostacyclin and Its Therapeutic Potential (1982) (1)
Effects of defibrotide on infarct size and regional myocardial blood flow on the ischaemic reperfused rabbit heart. (1989) (1)
Conversion of angiotensin I to angiotensin II in isolated strips of arterial smooth muscle (T). (1970) (0)
Pharmaceutical combination, processes for their preparation and their use (1977) (0)
Endothelin and the Homeostatic Function of the Endothelial Cell (1992) (0)
Annual Review of Pharmacology (1964) (0)
1001 – HYPERALGESIA, INFLAMMATORY OEDEMA AND PROSTAGLANDINS (PGs) (1977) (0)
The blockade of the local generation of prostaglandins explains the analgesic action of aspirin. (1973) (0)
The inhibition of bradykininases by trasylol in dog's blood (1969) (0)
Role of tyrosine kinase and NFκB in the induction of nitric oxide synthase by lipoteichoic acid in cultured murine macrophages (1995) (0)
Cultured astrocytoma cells release a nitric oxide-like factor (1990) (0)
The use of isolated organs for detecting active substances in the circulating blood (2011) (0)
Identification ofendothelin 1andbigendothelin 1insecretory vesicles isolated frombovineaortic endothelial cells (1995) (0)
RE-ADDRESSING RELATIVE SELECTIVITIES. AUTHOR'S REPLY (1997) (0)
UNIVERSITY OF WEST BOHEMIA IN PILSEN DEPARTMENT OF CYBERNETIC Optimization of Features for Robust Speaker Recognition (2005) (0)
Intracellular release of PAF contributes to the induction of nitric oxide synthase in a model of gram-positive shock (1995) (0)
Introduction (1945) (0)
[New perspectives in the knowledge of endothelial mediators: their repercussion in clinical medicine. Fernandez-Cruz Lecture]. (1991) (0)
Pharmacology. ET touches down in Houston. (1993) (0)
THE RELATIONSHIP BETWEEN THE CATHOLIC CHURCH AND THE CIVIL SOCIETY IN THE CZECH REPUBLIC (2013) (0)
BIOASSAY ADVENTURE ON THE WAY TO PROSTACYCLIN (1984) (0)
Immunogold Localization of Endothelin-1 in Endothelial Cells (1996) (0)
Summing up: Dr. J.R. Vane (1979) (0)
Cardioprotective effects of prostaglandin E1 in the rabbit are abolished by a blocker of ATP-sensitive potassium channels (1995) (0)
Number of acute coronary syndromes in Mostar regional hospital before and during the war in Bosnia and Herzegovina A plea for preservation of the pelvic autonomic n e rv e s (1999) (0)
Tyrosine kinase is essential for induction of COX-2 in endothelial cells by LPS or inflammatory cytokines (1995) (0)
442P PLATELET-DERIVED NITRIC OXIDE IN HYPERTENSIVE AND NORMOTENSIVE CONTROL SUBJECTS (2007) (0)
CONCLUDING REMARKS ON CIRCULATORY ACTIONS OF PROSTACYCLIN AND THROMBOXANE (1981) (0)
Irish Society of Gastroenterology (1995) (0)
Mast cell derived relaxing factor and the effect of nitric oxide generators on mast cell histamine release (1990) (0)
Inhibition of EDRF Synthesis Reduces the Pentagastrin-Induced Hyperaemia of the Rat Gastric Mucosa (1991) (0)
The Inhibition by Trasylol of Bradykininases in Dog’s Blood (1970) (0)
Contents, Vol. 101, 1993 (1993) (0)
Perspectives in prostaglandin research : proceedings of the Winter Seminar of the Japanese Inflammation Society, Tokyo, January 28-29, 1983 (1983) (0)
2nd International Symposium on Endothelium-Derived Vasoactive Factors (1992) (0)
N omega nitro l arginine and n omega nitro l arginyl l phenylalanine inhibit endothelium dependent vasodilatations in vitro in rabbits and in vivo in the anesthetized rat (1990) (0)
EFFECTS OF IBUPROFEN ON INDUCIBLE NITRIC OXIDE SYNTHASE, HAEMODYNAMICS AND ORGAN DYSFUNCTION IN A RAT MODEL OF SEPTIC SHOCK: 663 (1997) (0)
2nd International Symposium on Endothelium-Derived Vasoactive Factors (Part 2 of 11) (1992) (0)
Chemical mediators and the anti-thrombotic properties of endothelial cells. (1989) (0)
ROLE OF BACTERIA AND ENDOTOXIN IN NITRIC OXIDE SYNTHASE INDUCTION AND RAT INTESTINAL INJURY PROVOKED BY NON-STEROID ANTI-INFLAMMATORY AGENTS (2007) (0)
The NSAID roller coaster: more about rofecoxib (2006) (0)
Differences in the actions of histamine, gastrin and a related tetrapeptide on gastric secretion in cats (2004) (0)
Prostacyclin: its biosynthesis, actions and clinical potential. (1981) (0)
The effect of paludrine on gastric secretion in man. (1948) (0)
Erratum (1976) (0)
Endothelin IV : proceedings of the Fourth International Conference on Endothelin held at the William Harvey Research Institute, London, U.K., April 23-26, 1995 (1995) (0)
Finding the resources to fight tropical diseases. (1979) (0)
The present status of eicosanoids and related substances in the control of the cardiovascular system. (1991) (0)
Nitric oxide isamediator ofthedecrease incytochrome P450-dependent metabolism caused byimmunostimulants (1993) (0)
Fatty acids, derivatives thereof and drugs containing it (1979) (0)
J774 Cells metabolise glyceryl trinitrate by an enzymic pathway which can be induced by E. colt lipopolysaccharide (1992) (0)
The Release of Vasoactive Mediators from Arterial and Venous Cultured Endothelial Cells (1991) (0)
(All-Z) -5,8,11,14,17-eicosapentaenoic acid and / or derivatives thereof containing formulations, as well as processes for their preparation (1978) (0)
113 NITRIC OXIDE AND MULTIPLE ORGAN FAILURE (1995) (0)
Thapsigargin Differentiates Between Edrf and Prostacyclin Release Induced by Shear-Stress or Agonists (1993) (0)
Tryptamine and Serotonin Receptors (1962) (0)
Prostacyclin is a Heparin-Sparing Agent during Haemodialysis (1978) (0)

This paper list is powered by the following services:

Other Resources About John Vane

en.wikipedia.org

What Schools Are Affiliated With John Vane?

John Vane is affiliated with the following schools:

John Vane's Academic­Influence.com Rankings